It has demonstrated significant clinical activity in patients with metastatic melanoma, renal cell carcinoma, microsatellite instable colorectal cancer and non-small cell lung cancer and response rates are higher compared to single agent anti-PD-1 therapy. The gene discussed is RPL17; the disease is non-small cell lung carcinoma.